AC Immune, Takeda sign worldwide option and license agreement

Takeda (TAK) and AC Immune (ACIU) announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease. AC Immune will be responsible for completing the ABATE trial. Following option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities as well as worldwide commercialization. Under the terms of the agreement, AC Immune will receive an upfront payment of $100M and be eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1B if all related milestones are achieved over the course of the agreement. Upon commercialization, AC Immune will be entitled to receive tiered double-digit royalties on worldwide net sales.